 |
|
|
| |
QUARTZ-I: Retreatment of HCV Genotype 1 DAA-failures With
Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Fred Poordad1, Michael Bennett 2, Thomas E Sepe3, Eric Cohen4, Robert W Reindollar5, Gregory Everson6, Raymond W Phillips7, Asma Siddique8, J Greg Sullivan9, Terry D Box10, Bo Fu4, Tami Pilot-Mati as4,
Manal Abunimeh4, Daniel E Cohen4, Ziad Younes11
1The Texas Liver Insti tute/University of Texas Health Science Center, San Antonio, Texas, United States; 2Medical Associates Research Group, San Diego, California, United States; 3Liver Center, University Gastroenterology, Providence, Rhode Island, United States; 4AbbVie Inc., North Chicago, Illinois, United States;
5Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, North Carolina, United States; 6University of Colorado Denver School of Medicine, Aurora, Colorado, United States; 7Gastroenterology Group of Naples PA, Naples, Florida, United States; 8Virginia Mason Hospital and Medical Center, Seatt le,
Washington, United States; 9Parkway Medical Center, Birmingham, Alabama, United States; 10Clinical Research Centers of America, Murray, Utah, United States; 11GastroOne, Germantown, Tennessee, United States
|
| |
|
|
|
|
|
